Catalyst Pharmaceuticals, Inc. CPRX
Jul 15, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- +34.92%
- 1 year
- +43.86%
- Market cap
- 3.85B
- Profit margin
- 37.08%
- YTD return
- +34.92%
- 1-year return
- +43.86%
- Open
- 31.49
- Previous close
- 31.49
- Day's range
- 31.49 – 31.49
- Earnings date
- Aug 5, 2026
2Y +14.49 (+85.24%)
Key statistics
- Enterprise value
- 3.10B
- PEG ratio
- 2.07
- Price / sales
- 0.00
- Price / book
- 3.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 23.65%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.48 | — | — | — |
| May 11, 2026 | Mar 31, 2026 | 0.64 | 0.52 | -0.12 | -18.75% |
| Feb 25, 2026 | Dec 31, 2025 | 0.42 | 0.42 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.51 | 0.43 | -0.08 | -15.69% |
| Aug 6, 2025 | Jun 30, 2025 | 0.58 | 0.43 | -0.15 | -25.86% |
| May 7, 2025 | Mar 31, 2025 | 0.53 | 0.47 | -0.06 | -11.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| May 8, 2026 | Citigroup | down | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 7, 2025 | Citigroup | main | Buy | Buy |
| Mar 3, 2025 | Baird | main | Outperform | Outperform |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 182
- Website
- catalystpharma.com
News
Chuck Royce's Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts 
California State Teachers Retirement System Acquires 30,717 Shares of Catalyst Pharmaceuticals, Inc. $CPRX 
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst 
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals 
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger 
Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026 
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data 
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses 
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? 
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Your note
Sign in to keep a note on CPRX — it syncs with the Stock Master app.